share_log

Transcode Therapeutics | DEF 14A: Definitive information statements

Transcode Therapeutics | DEF 14A: Definitive information statements

Transcode Therapeutics | DEF 14A：股東委託書決議
美股SEC公告 ·  2024/10/29 04:05

Moomoo AI 已提取核心訊息

TransCode Therapeutics, Inc. has announced a Special Meeting of Stockholders to be held virtually on November 22, 2024. The meeting will address three key proposals: the ratification of a securities issuance and sale agreement with ThinkEquity LLC, an amendment to the company's charter to effect a reverse stock split, and a proposal to adjourn the meeting if necessary to solicit additional votes. The reverse stock split aims to increase the market price of TransCode's common stock to comply with Nasdaq's minimum bid price requirement. The Board has recommended a range for the reverse stock split, from one-for-ten to one-for-forty, with the exact ratio to be determined by the Board. The ratification proposal seeks to address a compliance issue with Nasdaq Listing Rule 5635(d), which requires shareholder approval for certain transactions. The Board has fixed October 25, 2024, as the record date for stockholders entitled to vote. The company has also addressed potential delisting risks if compliance with Nasdaq's continued listing requirements is not regained.
TransCode Therapeutics, Inc. has announced a Special Meeting of Stockholders to be held virtually on November 22, 2024. The meeting will address three key proposals: the ratification of a securities issuance and sale agreement with ThinkEquity LLC, an amendment to the company's charter to effect a reverse stock split, and a proposal to adjourn the meeting if necessary to solicit additional votes. The reverse stock split aims to increase the market price of TransCode's common stock to comply with Nasdaq's minimum bid price requirement. The Board has recommended a range for the reverse stock split, from one-for-ten to one-for-forty, with the exact ratio to be determined by the Board. The ratification proposal seeks to address a compliance issue with Nasdaq Listing Rule 5635(d), which requires shareholder approval for certain transactions. The Board has fixed October 25, 2024, as the record date for stockholders entitled to vote. The company has also addressed potential delisting risks if compliance with Nasdaq's continued listing requirements is not regained.
TransCode Therapeutics公司宣佈將於2024年11月22日舉行股東特別會議，會議將以虛擬形式舉行。 會議將討論三項關鍵提案：批准與ThinkEquity LLC的證券發行和銷售協議，修訂公司章程以實施股票的比例逆向拆分，以及在必要時延期會議以徵求額外的投票。 逆向股票拆分旨在提高TransCode普通股的市場價格，以符合納斯達克的最低買入價要求。 董事會已建議逆向股票拆分的區間，從一股拆分爲十股到一股拆分爲四十股，具體比例將由董事會確定。 批准提案旨在解決與納斯達克列出規則5635(d)的合規問題，該規則要求股東就某些交易進行批准。 董事會已確定2024年10月25日爲有權投票的股東記錄日期。 該公司還已針對可能發生的被納斯達克除牌風險作出了回應，如果未恢復納斯達克的繼續上市要求合規性。
TransCode Therapeutics公司宣佈將於2024年11月22日舉行股東特別會議，會議將以虛擬形式舉行。 會議將討論三項關鍵提案：批准與ThinkEquity LLC的證券發行和銷售協議，修訂公司章程以實施股票的比例逆向拆分，以及在必要時延期會議以徵求額外的投票。 逆向股票拆分旨在提高TransCode普通股的市場價格，以符合納斯達克的最低買入價要求。 董事會已建議逆向股票拆分的區間，從一股拆分爲十股到一股拆分爲四十股，具體比例將由董事會確定。 批准提案旨在解決與納斯達克列出規則5635(d)的合規問題，該規則要求股東就某些交易進行批准。 董事會已確定2024年10月25日爲有權投票的股東記錄日期。 該公司還已針對可能發生的被納斯達克除牌風險作出了回應，如果未恢復納斯達克的繼續上市要求合規性。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    美聯儲暫停降息，你如何調整持倉？
    美聯儲宣布基準利率維持在4.25%—4.50%不變，符合市場預期。你會如何配置資產？ 展开
    FOMC新聞發佈會，2025年1月29日